Explanipedia

A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burden Open

Frank Lin, David Espinoza, John P. Grady, Peey‐Sei Kok, Sarah Chinchen , et al. · 2025

PATH-52. Understanding the prevalence of MTAP and CDKN2A/B deletion in gliomas by next generation sequencing Open

Natalie Southi, Hao‐Wen Sim, John P. Grady, Laveniya Satgunaseelan, Min Huang , et al. · 2025

BACKGROUND CDKN2A/B (cyclin-dependent kinase inhibitor 2A/B) gene alterations are integral to the diagnosis and prognostication of IDH-mutant gliomas. CDKN2A/B status is commonly assessed by next generation sequencing (NGS) or inferred fro…

High-throughput 3D engineered paediatric tumour models for precision medicine Open

MoonSun Jung, Valentina Poltavets, Joanna N. Skhinas, Gábor Tax, Alvin Kamili , et al. · 2025

Precision medicine for paediatric and adult cancers that incorporates drug sensitivity profiling can identify effective therapies for individual patients. However, obtaining adequate biopsy samples for high-throughput (HTP) screening remai…

A Robust BERT-Based Deep Learning Model for Automated Cancer Type Extraction from Unstructured Pathology Reports Open

Minh Tran, Jeffery C. Chan, Min Huang, Maya Kansara, John P. Grady , et al. · 2025

The accurate extraction of clinical information from electronic medical records is particularly critical to clinical research but require much trained expertise and manual labor. In this study we developed a robust system for automated ext…

Automating Precision Oncology Literature Curation: A Decision Tree Approach Using Large Language Models Open

Frank Lin, Minh Ngoc Tran, Subotheni Thavaneswaran, John P. Grady, Maya Kansara , et al. · 2025

The curation of precision oncology knowledge bases requires intensive screening of scientific literature. Large Language Models (LLMs) offer potential to assist with knowledge extraction and curation through automated abstract screening, t…

Genetic Control of the Transcriptional Response to Active Tuberculosis Disease and Treatment Open

John P. Grady, Alexander S. Leonard, Houcheng Li, Lingzhao Fang, Hubert Pausch , et al. · 2025

A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling Open

Subotheni Thavaneswaran, Hao‐Wen Sim, John P. Grady, David Espinoza, Min Huang , et al. · 2024

Background TRK-inhibitors have demonstrated efficacy across several cancers with NTRK fusions. Their activity in cancers with NTRK overexpression remains unclear. Methods This trial enrolled patients with advanced cancers harboring NTRK fu…

Engineered paediatric tumours retain maintains tumour genotype and phenotype for precision medicine Open

MoonSun Jung, Valentina Poltavets, Joanna N. Skhinas, Gábor Tax, Alvin Kamili , et al. · 2024

Precision medicine for paediatric and adult cancers that includes drug sensitivity profiling, can identify effective therapies for individual patients. However, obtaining adequate biopsy samples for high-throughput (HTP) screening remains …

A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation Open

Subotheni Thavaneswaran, Frank Lin, John P. Grady, David Espinoza, Min Huang , et al. · 2024

A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content Open

Radwa Sharaf, Dexter X. Jin, John P. Grady, Christine E. Napier, Ericka M. Ebot , et al. · 2023

Tumor cells need to activate a telomere maintenance mechanism, enabling limitless replication. The bulk of evidence supports that sarcomas predominantly use alternative lengthening of telomeres (ALT) mechanism, commonly associated with alt…

A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations Open

Subotheni Thavaneswaran, Maya Kansara, Frank Cheau‐Feng Lin, David Espinoza, John P. Grady , et al. · 2023

Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion Open

Subotheni Thavaneswaran, Wei Yen Chan, Ray Asghari, John P. Grady, Maegan Deegan , et al. · 2022

A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers Open

Subotheni Thavaneswaran, Frank Lin, Maya Kansara, John P. Grady, David Espinoza , et al. · 2022

Immune checkpoint blockade impedes the negative regulatory signals for T-cell response and permits more effective immune detection and eradication of cancer cells. This single-arm phase II clinical trial (ACTRN12616001019493) within the Mo…

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology Open

Frank Lin, Subotheni Thavaneswaran, John P. Grady, Mandy L. Ballinger, Maya Kansara , et al. · 2021

While several resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world issues limit access to drugs. There is a need for a pragmatic, evidence-based, context-adapted tool to guide c…

A Signal-seeking Phase Iia Trial of Palbociclib in Advanced Cancers With Cell Cycle Pathway Alterations – A Substudy of the Molecular Screening and Therapeutics (Most) Program Open

Subotheni Thavaneswaran, Lucille Sebastian, Maya Kansara, Mandy L. Ballinger, David Espinoza , et al. · 2021

BACKGROUND: The D-type cyclin and cyclin dependent kinase 4/6 (CDK) complex phosphorylates retinoblastoma protein, thereby driving cell cycle progression. This process is blocked by inhibitors of CDK4/6. As part of the Molecular Screening …

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology Open

Frank Lin, Subotheni Thavaneswaran, John P. Grady, Mandy L. Ballinger, Maya Kansara , et al. · 2020

BACKGROUND While several key resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world issues limit access to drugs. There is a need for a pragmatic, evidence-based, context-adapted …

Molecular patterns in salivary duct carcinoma identify prognostic subgroups Open

Simon A. Mueller, Marie Gauthier, James Blackburn, John P. Grady, Spiridoula Kraitsek , et al. · 2020

Abstracts from USCAP 2020: Head and Neck Pathology (1235-1315) Open

Jason L. Hornick, Rhonda K. Yantiss, Laura W. Lamps, Cme Subcommittee, Steven D. Billings , et al. · 2020

Abstracts from USCAP 2020: Head and Neck Pathology (1235-1315) Open

Jason L. Hornick, Rhonda K. Yantiss, Laura W. Lamps, Cme Subcommittee, Steven D. Billings , et al. · 2020

Chromosome arm aneuploidies shape tumour evolution and drug response Open

Ankit Shukla, Thu H.M. Nguyen, Sarat Moka, Jonathan Ellis, John P. Grady , et al. · 2020

Chromosome arm aneuploidies (CAAs) are pervasive in cancers. However, how they affect cancer development, prognosis and treatment remains largely unknown. Here, we analyse CAA profiles of 23,427 tumours, identifying aspects of tumour evolu…

Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors Open

Amanda M. Smith, Christine Zhang, Alexandre S. Cristino, John P. Grady, J. Lynn Fink , et al. · 2020

// Amanda M. Smith 1 , 4 , * , Christine R.C. Zhang 1 , 4 , * , Alexandre S. Cristino 1 , 6 , John P. Grady 1 , 5 , J. Lynn Fink 1 and Andrew S. Moore 1 , 2 , 3 1 The University of Queensland Diamantina Institute, The University of Queensl…

Development and validation of a targeted gene sequencing panel for application to disparate cancers Open

Mark J. McCabe, Marie Gauthier, Chia-Ling Chan, Tanya Thompson, Sunita M C De Sousa , et al. · 2019

PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors Open

Amanda M. Smith, Christine Zhang, Alexandre S. Cristino, John P. Grady, J. Lynn Fink , et al. · 2019

Kinases such as MEK are attractive targets for novel therapy in cancer, including acute myeloid leukaemia (AML). Acquired and inherent resistance to kinase inhibitors, however, is becoming an increasingly important challenge for the clinic…

Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases Open

Mark J. McCabe, Mark Pinese, Chia‐Ling Chan, Nisa Sheriff, Tanya Thompson , et al. · 2019

Adrenocortical carcinoma is a rare malignancy with a poor prognosis and few treatment options. Molecular characterization of this cancer remains limited. We present a case of an adrenocortical carcinoma (ACC) in a 37-yr-old female, with du…

The cancer molecular screening and therapeutics program (MoST): A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies Open

Subotheni Thavaneswaran, Lucille Sebastian, Mandy L. Ballinger, Mark J. Cowley, John P. Grady , et al. · 2018

Background: Innovative approaches are needed to translate molecular opportunities into clinical care. MoST tests a novel paradigm for evaluation of biomarker-driven treatments (tx) for patients (pts) with advanced cancer, with a particular…

Inherited pathogenic mitochondrial DNA mutations and gastrointestinal stem cell populations Open

Tianhong Su, John P. Grady, Sorena Afshar, Stuart A.C. McDonald, Robert W. Taylor , et al. · 2018

Inherited mitochondrial DNA (mtDNA) mutations cause mitochondrial disease, but mtDNA mutations also occur somatically and accumulate during ageing. Studies have shown that the mutation load of some inherited mtDNA mutations decreases over …

Graphical user interface for simultaneous profiling of activity patterns in multiple neuronal subclasses Open

R. Ryley Parrish, John P. Grady, Neela K. Codadu, Claudia Racca, Andrew J. Trevelyan · 2018

Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability Open

Ankit K. Dutta, J. Lynn Fink, John P. Grady, Gareth J. Morgan, Charles G. Mullighan , et al. · 2018

Dissecting the neuronal vulnerability underpinning Alpers’ syndrome: a clinical and neuropathological study Open

Hannah Hayhurst, Maria‐Eleni Anagnostou, Helen Judith Bogle, John P. Grady, Robert W. Taylor , et al. · 2018

Alpers’ syndrome is an early‐onset neurodegenerative disorder often caused by biallelic pathogenic variants in the gene encoding the catalytic subunit of polymerase‐gamma ( POLG ) which is essential for mitochondrial DNA (mt DNA ) replicat…

mt DNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease Open

John P. Grady, Sarah J. Pickett, Yi Shiau Ng, Charlotte L. Alston, Emma L. Blakely , et al. · 2018

Mitochondrial disease associated with the pathogenic m.3243A>G variant is a common, clinically heterogeneous, neurogenetic disorder. Using multiple linear regression and linear mixed modelling, we evaluated which commonly assayed tissue (b…

John P. Grady YOU? Author Swipe